CA2483857A1 - Use of dimesna for mitigating taxane induced neurotoxicity - Google Patents

Use of dimesna for mitigating taxane induced neurotoxicity Download PDF

Info

Publication number
CA2483857A1
CA2483857A1 CA002483857A CA2483857A CA2483857A1 CA 2483857 A1 CA2483857 A1 CA 2483857A1 CA 002483857 A CA002483857 A CA 002483857A CA 2483857 A CA2483857 A CA 2483857A CA 2483857 A1 CA2483857 A1 CA 2483857A1
Authority
CA
Canada
Prior art keywords
taxane
antineoplastic agent
drug
taxane antineoplastic
ethane sulfonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002483857A
Other languages
English (en)
French (fr)
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNumerik Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2483857A1 publication Critical patent/CA2483857A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002483857A 2002-04-30 2003-04-29 Use of dimesna for mitigating taxane induced neurotoxicity Abandoned CA2483857A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/135,975 US8710095B2 (en) 2002-04-30 2002-04-30 Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US10/135,975 2002-04-30
PCT/US2003/013518 WO2003092675A1 (en) 2002-04-30 2003-04-29 Drugs for mitigating taxane-induced neurotoxicity

Publications (1)

Publication Number Publication Date
CA2483857A1 true CA2483857A1 (en) 2003-11-13

Family

ID=29249584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002483857A Abandoned CA2483857A1 (en) 2002-04-30 2003-04-29 Use of dimesna for mitigating taxane induced neurotoxicity

Country Status (8)

Country Link
US (1) US8710095B2 (https=)
EP (1) EP1503748B1 (https=)
JP (2) JP5416327B2 (https=)
AT (1) ATE554753T1 (https=)
AU (1) AU2003225253B2 (https=)
CA (1) CA2483857A1 (https=)
ES (1) ES2381968T3 (https=)
WO (1) WO2003092675A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
EP1991237B1 (en) * 2005-12-13 2015-02-25 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
EP2004175A4 (en) * 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
CN101790377A (zh) * 2007-08-31 2010-07-28 国立大学法人九州大学 抗癌剂导致的末梢神经障碍的预防或减轻剂
CA2706378C (en) 2007-11-20 2017-09-12 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
ES2476602T3 (es) * 2008-03-14 2014-07-15 Bionumerik Pharmaceuticals, Inc. Composiciones y métodos quimioprotectores
CN102014891B (zh) * 2008-03-14 2013-12-18 比奥纽默里克药物公司 增加癌症患者存活时间的化合物的组合物和使用方法
CA2717181C (en) * 2008-03-14 2013-10-15 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
US20090232906A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
UY33203A (es) 2010-01-27 2011-08-31 Takeda Pharmaceutical Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno
US11471431B2 (en) * 2010-09-16 2022-10-18 Lantern Pharma Inc. Increasing cancer patient survival time by administration of dithio-containing compounds
WO2015070323A1 (en) * 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
KR102607967B1 (ko) * 2016-12-19 2023-11-29 메르크 파텐트 게엠베하 단백질 키나제 억제제 및 추가 화학요법제의 조합물
CA3060266A1 (en) 2017-04-17 2018-10-25 Indiana University Research And Technology Corporation Prevention and reversal of inflammation induced dna damage

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010076A1 (en) * 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
FR2722987B1 (fr) * 1994-07-29 1997-05-16 Synthelabo Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux
US6025488A (en) * 1994-11-14 2000-02-15 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
DE19617802A1 (de) 1996-05-03 1997-11-06 Basf Ag Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen
ES2170414T3 (es) 1996-09-23 2002-08-01 Bionumerik Pharmaceuticals Inc Reduccion de efectos toxicos del carboplatino usando ditioeteres.
US6037336A (en) 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
CN1082047C (zh) 1996-10-01 2002-04-03 比奥纽默里克药物公司 生产巯基链烷磺酸盐和磷酸盐及其衍生物的方法
US6160167A (en) 1998-04-21 2000-12-12 Bionumerik Pharmaceuticals, Inc. Mercaptans and disulfides
US6172119B1 (en) 1999-02-09 2001-01-09 Bionumerik Pharmaceuticals, Inc. Method of treating acute renal failure
US5998479A (en) 1999-02-09 1999-12-07 Bionumerik Pharmaceuticals, Inc. Method of treating adult respiratory syndrome
US6177411B1 (en) 1999-02-09 2001-01-23 Bionumerik Pharmaceuticals, Inc. Method for treating heavy metal poisoning
US6197831B1 (en) 1999-02-09 2001-03-06 Bionumerik Pharmaceuticals, Inc. Method of treating septic shock
US6075053A (en) 1999-02-09 2000-06-13 Bionumerik Pharmaceuticals, Inc. Method of reducing or reversing neuropathy
US6034126A (en) 1999-05-24 2000-03-07 Bionumerik Pharmaceuticals, Inc. Method for treating glycol poisoning
US6077838A (en) 1999-06-08 2000-06-20 Bionumerik Pharmaceuticals, Inc. Method of treating hangover
US6143796A (en) 1999-09-02 2000-11-07 Bionumerik Pharmaceuticals, Inc. Method for reducing development of free radical induced malignancies
US6468993B1 (en) 1999-10-04 2002-10-22 Bionumerik Pharmaceuticals, Inc. Method for reducing development of osteoporosis
US6251881B1 (en) 1999-10-21 2001-06-26 Frederick H. Hausheer Method of treating diabetic angiopathy
US6043274A (en) 1999-10-21 2000-03-28 Bionumerik Pharmaceuticals, Inc. Method of treating diabetic cardiomyopathy
US6031006A (en) 1999-10-21 2000-02-29 Bionumerik Pharmaceuticals, Inc. Method of treating diabetic nephropathy
US6100247A (en) 1999-10-21 2000-08-08 Bionumerik Pharmaceuticals, Inc. Method of treating diabetic neuropathy
US6274622B1 (en) 1999-10-27 2001-08-14 Frederick H. Hausheer Method of treating diabetic ophthalmopathy
US6525037B1 (en) 2000-02-25 2003-02-25 Bionumerik Pharmaceuticals, Inc. Method of treating atherosclerosis and complications resulting therefrom
AU2000239101A1 (en) * 2000-03-22 2001-10-03 Neopharm, Inc. A method of administering liposomal encapsulated taxane
US6245815B1 (en) 2000-04-15 2001-06-12 Bionumerik Pharmaceuticals, Inc. Method of treating alcoholism and complications resulting therefrom
US6468963B1 (en) 2000-05-01 2002-10-22 Bionumerik Pharmaceuticals, Inc. Methods and formulations for reducing toxicity associated with diabetes treatments
FR2811987A1 (fr) 2000-07-18 2002-01-25 Expansia Sa Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium
US6225295B1 (en) 2000-09-27 2001-05-01 Frederick H. Hausheer Method of treating acetaminophen overdose
US6291441B1 (en) 2000-09-27 2001-09-18 Frederick H. Hausheer Method of treating inflammatory bowel disorders
US6255355B1 (en) 2001-01-06 2001-07-03 Seetharamulu Peddaiahgari Method of inhibiting angiogenesis
EP1351677A4 (en) 2001-01-19 2009-08-19 Bionumerik Pharmaceuticals Inc CANCER TREATMENT METHOD
US6352979B1 (en) 2001-08-20 2002-03-05 Lucinda Lizcano Method of treating snakebite and complications resulting therefrom
US7176192B2 (en) 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US6596320B1 (en) 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US6504049B1 (en) 2002-04-30 2003-01-07 Bionumerik Pharmaceuticals, Inc. Process for synthesizing pharmaceutically active disulfide salts
US20040014730A1 (en) 2002-07-10 2004-01-22 Frederick Hausheer Formulations and methods of reducing toxicity of anti-infective agents
MXPA05006721A (es) 2002-12-21 2005-09-30 Bionumerik Pharmaceuticals Inc Metodo para tratamiento de pacientes expuestos a agentes quimicos toxicos.
US20040152774A1 (en) 2003-02-04 2004-08-05 Hausheer Frederick H. Method of protecing against tissue extra vasation injury
CA2548497C (en) 2003-12-17 2009-06-09 Bionumerik Pharmaceuticals, Inc. Process for synthesizing disulfides

Also Published As

Publication number Publication date
EP1503748B1 (en) 2012-04-25
ATE554753T1 (de) 2012-05-15
AU2003225253A1 (en) 2003-11-17
US20030203960A1 (en) 2003-10-30
WO2003092675A1 (en) 2003-11-13
JP2011140521A (ja) 2011-07-21
US8710095B2 (en) 2014-04-29
AU2003225253B2 (en) 2008-09-04
EP1503748A1 (en) 2005-02-09
EP1503748A4 (en) 2009-10-21
JP2005525409A (ja) 2005-08-25
JP5416327B2 (ja) 2014-02-12
ES2381968T3 (es) 2012-06-04

Similar Documents

Publication Publication Date Title
AU2003225253B2 (en) Drugs for mitigating taxane-induced neurotoxicity
Pasetto et al. Oxaliplatin-related neurotoxicity: how and why?
CN100411628C (zh) 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用
AU2014251087B2 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
NZ510504A (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
JP2005525409A5 (https=)
US4609647A (en) Cytidyl diphosphocholine-drug composition and process
KR20020060226A (ko) 배합 화학요법
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1273296B1 (en) Combination of acetyldinaline and docetaxel
US7998973B2 (en) Tivozanib and temsirolimus in combination
EP3127544B1 (en) Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer
JP2004523518A (ja) より効能が大きく副作用の少ない癌治療方法
AU2002251763A1 (en) Method for treating cancer
US20040086536A1 (en) Therapeutic agents and treatment kits for hypertrophic pyloric stenosis
US20030134893A1 (en) Combination chemotherapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20121001